Hepatitis C and pulmonary fibrosis

Hepatitis Monthly

Volumn 11, Issue 2, 2011, Pages 71-73

  Aliannejad, Rasoul ^a   Ghanei, Mostafa ^b  

^a GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hepatitis C; Pulmonary fibrosis

Indexed keywords

ALPHA INTERFERON; HEPATITIS C ANTIBODY; INTERFERON; VIRUS RNA;

CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL COUNT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERSTITIAL PNEUMONIA; LUNG FIBROSIS; LUNG LAVAGE; LYMPHOCYTE COUNT; NEUTROPHIL COUNT; PATHOGENESIS; PREVALENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOIDOSIS; SYSTEMATIC REVIEW; VIRUS REPLICATION;

EID: 79952468203     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Editorial

References (32)

1. Zignego AL, Brechot C. Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol. 1999;31(2):369-76.
2. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 1999;42(10):2204-12.
3. Kanazawa H, Mamoto T, Hirata K, Yoshikawa J. Interferon therapy induces the improvement of lung function by inhaled corticosteroid therapy in asthmatic patients with chronic hepatitis C virus infection: a preliminary study. Chest. 2003;123(2):600-3.
4. Kanazawa H, Yoshikawa J. Accelerated decline in lung function and impaired reversibility with salbutamol in asthmatic patients with chronic hepatitis C virus infection: a 6-year follow-up study. Am J Med. 2004;116(11):749-52.
5. Kanazawa H, Hirata K, Yoshikawa J. Accelerated decline of lung function in COPD patients with chronic hepatitis C virus infection: a preliminary study based on small numbers of patients. Chest. 2003;123(2):596-9.
6. Erol S, Saglam L, Ozbek A, Kadanali A. Hepatitis C Virus Infection and Chronic Obstructive Pulmonary Disease. Hepat Mon. 2009;9(1):39-44.
7. Krowka MJ, Dickson ER, Cortese DA. Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue. Chest. 1993;104(2):515-21.
8. Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med. 1996;17(1):17-33.
9. Bombardieri S, Paoletti P, Ferri C, Di Munno O, Fornal E, Giuntini C. Lung involvement in essential mixed cryoglobulinemia. Am J Med. 1979;66(5):748-56.
10. Viegi G, Fornai E, Ferri C, Di Munno O, Begliomini E, Vitali C, et al. Lung function in essential mixed cryoglobulinemia: a short-term follow-up. Clin Rheumatol. 1989;8(3):331-8.
11. Manganelli P, Salaffi F, Subiaco S, Carotti M, Cervini C, Consigli G, et al. Bronchoalveolar lavage in mixed cryoglobulinaemia associated with hepatitis C virus. Br J Rheumatol. 1996;35(10):978-82.
12. Ferri C, La Civita L, Fazzi P, Solfanelli S, Lombardini F, Begliomini E, et al. Interstitial lung fibrosis and rheumatic disorders in patients with hepatitis C virus infection. Br J Rheumatol. 1997;36(3):360-5.
13. Aisa Y, Yokomori H, Kashiwagi K, Nagata S, Yanagisawa R, Takahashi M, et al. Polymyositis, pulmonary fibrosis and malignant lymphoma associated with hepatitis C virus infection. Intern Med. 2001;40(11):1109-12.
14. Nocente R, Ceccanti M, Bertazzoni G, Cammarota G, Silveri NG, Gasbarrini G. HCV infection and extrahepatic manifestations. Hepatogastroenterology. 2003;50(52):1149-54.
15. Weidensaul D, Imam T, Holyst MM, King PD, McMurray RW. Polymyositis, pulmonary fibrosis, and hepatitis C. Arthritis Rheum. 1995;38(3):437-9.
16. Ueda T, Ohta K, Suzuki N, Yamaguchi M, Hirai K, Horiuchi T, et al. Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis. 1992;146(1):266-8.
17. Ohta K, Ueda T, Nagai S, Yamada K, Yamaguchi M, Nakano J, et al. [Pathogenesis of idiopathic pulmonary fibrosis--is hepatitis C virus involved?]. Nihon Kyobu Shikkan Gakkai Zasshi. 1993;31(Suppl):32-5.
18. Irving WL, Day S, Johnston ID. Idiopathic pulmonary fibrosis and hepatitis C virus infection. Am Rev Respir Dis. 1993;148(6 Pt 1):1683-4.
19. Meliconi R, Andreone P, Fasano L, Galli S, Pacilli A, Miniero R, et al. Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis. Thorax. 1996;51(3):315-7.
20. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, et al. Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis. World J Gastroenterol. 2008;14(38):5880-6.
21. Kubo K, Yamaguchi S, Fujimoto K, Hanaoka M, Hayasaka M, Honda T, et al. Bronchoalveolar lavage fluid findings in patients with chronic hepatitis C virus infection. Thorax. 1996;51(3):312-4.
22. Yamaguchi S, Kubo K, Fujimoto K, Honda T, Sekiguchi M, Sodeyama T. Analysis of bronchoalveolar lavage fluid in patients with chronic hepatitis C before and after treatment with interferon alpha. Thorax. 1997;52(1):33-7.
23. Idilman R, Cetinkaya H, Savas I, Aslan N, Sak SD, Bastemir M, et al. Bronchoalveolar lavage fluid analysis in individuals with chronic hepatitis C. J Med Virol. 2002;66(1):34-9.
24. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277-304.
25. Kula M, Gulmez I, Tutus A, Coskun A, Gursoy S, Oymak S. Impaired lung epithelial permeability in hepatitis C virus antibody positive patients detected by 99mTc-DTPA aerosol scintigraphy. Nucl Med Commun. 2002;23(5):441-6.
26. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 1996;25(3):283-91.
27. Karino Y, Hige S, Matsushima T, Toyota J. [Interstitial pneumonia induced by interferon therapy in type C hepatitis]. Nippon Rinsho. 1994;52(7):1905-9.
28. Rocca P, Dumortier J, Taniere P, Duperret S, Vial T, Cottin V, et al. [Induced interstitial pneumonitis: role of pegylated interferon alpha 2b]. Gastroenterol Clin Biol. 2002;26(4):405-8.
29. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. Glomerulonephritis in autopsy cases with hepatitis C virus infection. Intern Med. 1998;37(10):836-40.
30. Hunninghake GW, Schwarz MI. Does current knowledge explain the pathogenesis of idiopathic pulmonary fibrosis? A perspective. Proc Am Thorac Soc. 2007;4(5):449-52.
31. Koike K, Moriya K, Ishibashi K, Yotsuyanagi H, Shintani Y, Fujie H, et al. Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes. Proc Natl Acad Sci USA. 1997;94(1):233-6.
32. Alavian SM, Ahmadzad-Asl M, Lankarani KB, Shahbabaie MA, Bahrami Ahmadi A, Kabir A. Hepatitis C Infection in the General Population of Iran: A Systematic Review. Hepat Mon. 2009;9(3):211-23.